Ketamine intranasal - Hospira

Drug Profile

Ketamine intranasal - Hospira

Alternative Names: Ereska; Intranasal ketamine; PMI-100; PMI-150

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Innovative Drug Delivery Systems
  • Developer Hospira
  • Class Analgesics; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Acute pain
  • Discontinued Cancer pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jan 2012 Hospira terminates the phase III trial in Cancer pain (breakthrough pain) in USA (NCT00492388)
  • 31 Dec 2010 No development reported - Phase-III for Acute pain in Europe (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top